We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Chronic Lymphocytic Leukemia Increases Peripheral Blood Hematopoietic Stem Cells

By LabMedica International staff writers
Posted on 31 Dec 2020
Chronic lymphocytic leukemia (CLL) is an indolent B-cell malignancy invariably infiltrating the bone marrow. More...
The disease remains incurable, and after emergence of therapy, resistant disease patients succumb to infections because of secondary bone marrow failure.

The underlying mechanisms impairing normal hematopoiesis in patients with CLL are poorly defined. Mature, differentiated B cells, either pre- or post-germinal center, are considered the cell of origin of unmutated and mutated CLL, respectively. However, this paradigm has been challenged based on the observation of CLL-recurrent mutations present in a fraction of hematopoietic stem cells (HSCs).

Hematologists at the MRC Cambridge Stem Cell Institute (Cambridge, UK) and their colleagues assessed the frequency of hematopoietic stem and progenitor cells (HSPCs) in the peripheral blood (PB) of 69 individual patients with the diagnosis of CLL, and 21 age-matched healthy controls. PB samples were collected in the afternoon, when circulation of hematopoietic progenitors is known to reach its peak because of circadian oscillation.

To assess the absolute numbers of CD34+ cells, non-purified peripheral blood mononuclear cells from 5 mL PB were stained and gated for CD34 positivity and CD19 negativity to quantify the total amount of circulating hematopoietic progenitor cells, using precision counting beads (Biolegend, San Diego, CA, USA) and flow cytometry. Relative frequencies of HSPC subsets were assessed on CD34+-enriched cells using beads (Miltenyi Biotec, Bergisch Gladbach, Germany).

To assess differentiation capacity of HSPCs, 1 × 103 or 6 × 103 CD34+ cells were plated in duplicate in complete semisolid methylcellulose (STEMCELL Technologies, Vancouver, BC, Canada). Differentiated colonies were counted and scored based on morphology 14 days after culture in a humid environment at 37 °C using STEMCELL Technologies’ STEMVision camera and software.

The investigators reported that the absolute numbers of circulating HSPCs and found similar numbers of CD34+ cells to age-matched healthy individuals. The analyses revealed that common myeloid and myeloerythroid progenitors (CMPs-MEPs) (CD19CD34+CD38+CD45RACD10CD7) were more abundant in the PB of patients with CLL. Conversely, myelolymphoid progenitors (CD19CD34+CD38CD45RA+) were significantly decreased in patients’ blood compared with healthy controls. The HSC pool (CD19CD34+CD38CD45RA), defined as a pool of HSC and multipotent progenitors, is known to contain a heterogeneous pool of cells with different self-renewal and differentiation capacities, and was also more abundant in patients’ blood.

The authors concluded that their data provide further insights on the mechanisms causing cytopenia in patients with CLL and suggest that a pathologic mobilization of ST-HSCs is a contributing factor. The study was published on December 18, 2020 in the journal Blood Advances.

Related Links:
MRC Cambridge Stem Cell Institute
Biolegend
Miltenyi Biotec
STEMCELL Technologies



Gold Member
Veterinary Hematology Analyzer
Exigo H400
Serological Pipet Controller
PIPETBOY GENIUS
New
Automated Microscope
dIFine
New
Silver Member
Fibrinolysis Assay
HemosIL Fibrinolysis Assay Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








DIASOURCE (A Biovendor Company)

Channels

Immunology

view channel
Image: A simple blood test could replace surgical biopsies for early detecion of heart transplant rejection (Photo courtesy of Shutterstock)

Blood Test Detects Organ Rejection in Heart Transplant Patients

Following a heart transplant, patients are required to undergo surgical biopsies so that physicians can assess the possibility of organ rejection. Rejection happens when the recipient’s immune system identifies... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.